Blue Lotus
Viewing r2.a4 — Oct 6, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
Blue Lotus (Nymphaea nouchali var. caerulea, Nymphaeaceae) — also called Blue Water Lily and Sacred Blue Lily — is an aquatic perennial classified as a depressant and oneirogen. Its primary psychoactive alkaloid, nuciferine, has a receptor profile resembling atypical antipsychotics.[1] Nuciferine acts through 5-HT₂A antagonism, D2 partial agonism, and DAT inhibition, producing sedation with oneirogenic qualities.
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
Documented in ancient Egyptian ritual contexts spanning two millennia, N. caerulea was archaeochemically identified alongside the monoamine oxidase-inhibiting plant Peganum harmala in a Ptolemaic-era vessel.[2] Commercial availability expanded substantially in Western markets during the 2010s, though no controlled human pharmacological study has been published. The plant is unscheduled under United States federal law and major international treaties, with specific bans in Louisiana, Russia, and Poland.
Subjective effects include sedation, mild euphoria, anxiolysis, enhanced dream vividness, and dose-dependent perceptual disturbances. The experience varies by preparation — vaporized resin produces rapid onset with pronounced perceptual changes, while oral tea yields gentler, longer-lasting sedation. Unwanted effects at higher doses include confusion, hallucinations, and paranoia, particularly via inhaled routes.[3]
No tolerance, dependence, or withdrawal data have been published, and no formal toxicity studies exist.safety citation needed The dominant safety concern is product integrity — commercial products have been laced with synthetic cannabinoids[4] and may not contain authentic N. caerulea.[5] Clinical evidence rests on a single case series and military adverse event reports, with no controlled trials conducted.[3]
History[edit]
Ancient Egyptian use
Nymphaea caerulea held documented religious and cultural significance in ancient Egypt, appearing in tomb frescoes, papyrus scrolls, and funerary goods spanning more than two millennia. Blue lotus petals were found among funerary goods in the tomb of Tutankhamun (c. 1323 BCE).citation needed Depictions appear in the Book of the Dead and other ritual texts tied to resurrection and solar symbolism.[6] McDonald traced Egyptian lotus symbolism to approximately 2500 BCE, documenting the plant's influence on sacral worship throughout the Fertile Crescent.[7]
Tanasi and colleagues identified N. nouchali var. caerulea alongside Peganum harmala, fermented fruit, honey, and human biological fluids in a Ptolemaic-era Bes-vase (c. 2nd century BCE).[2] This provides direct archaeochemical evidence that blue lotus was incorporated into complex ritual preparations — potentially alongside monoamine oxidase inhibitors that could have potentiated its alkaloid effects. The pharmacological significance of blue lotus in Egyptian ritual remains an active area of scholarly interpretation, not a settled historical fact.
Western discovery and research
The plant was first scientifically described as Nymphaea caerulea by Savigny in 1798 in Décade égyptienne, a periodical of Napoleon's expedition to Egypt.[8] The modern accepted binomial Nymphaea nouchali var. caerulea was established in subsequent taxonomic revision by Verdcourt.
Modern era
Commercial availability expanded in Western markets during the 2010s–2020s, driven by online retail. Poklis and colleagues published among the first clinical-context reports in Western medical literature in 2017, analyzing blue lotus resin used in electronic cigarettes.[9] Published pharmacological research has focused on isolated nuciferine — predominantly sourced from Nelumbo nucifera — investigating its antipsychotic-like properties[1] and anti-obesity potential,[10][11] rather than whole N. caerulea preparations. No clinical trials studying N. caerulea in human subjects have been registered.
Archaeological evidence from Maya contexts includes Nymphaea ampla (White Water Lily), with apomorphine-class alkaloids identified in bulbs and roots, suggesting functionally analogous ritual use of Nymphaea species across cultures.[6] Minoan Crete cult scenes have been interpreted by some scholars as involving psychoactive Nymphaea species, though this remains contentious.[12]
In traditional African medicine, N. caerulea and related Nymphaea species have documented use for analgesic, sedative, anti-inflammatory, and aphrodisiac purposes.citation needed The closely related Nymphaea lotus demonstrates anxiolytic properties validated in rodent models.[13] No peer-reviewed ethnopharmacological study specifically addressing N. caerulea traditional medical use in Africa was identified.
Botanical Overview[edit]
Nymphaea nouchali var. caerulea belongs to the family Nymphaeaceae (water lilies). The species was originally described as Nymphaea caerulea by Savigny in 1798; the current accepted name reflects Verdcourt's subsequent revision placing it as a variety of the broader N. nouchali complex. It is distinct from Nymphaea lotus (White Lotus, same family) and Nelumbo nucifera (Sacred Lotus, family Nelumbonaceae) — both of which are frequently confused with it in commercial markets.
The plant is native to the Nile Valley and sub-Saharan Africa, where it grows in freshwater lakes, ponds, and slow-moving rivers.[8] It has been introduced to parts of the Indian subcontinent and Southeast Asia. N. caerulea is a day-blooming aquatic perennial, opening its flowers in the morning and closing them by afternoon — a behaviour linked to its solar symbolism in ancient Egyptian culture.[6]
Flowers are the primary identification feature: star-shaped with pointed petals in pale to vivid blue, arranged around a central cluster of yellow stamens. Leaves are round, waxy, and float on the water surface with a characteristic notch at the base where the petiole attaches. The plant should not be confused with Nelumbo nucifera, whose leaves and flowers rise above the water surface rather than floating on it. Species verification of commercial products is unreliable — analytical work has found that many products labeled as blue lotus do not match authenticated N. caerulea extracts.[5]
Flowers and occasionally rhizomes are harvested for psychoactive use, typically dried for tea or further processed into tinctures and concentrated resins.
Alkaloid Profile[edit]
Nuciferine, an aporphine alkaloid, is considered the primary psychoactive constituent of N. caerulea. Published analytical data on authenticated plant material show only trace alkaloid concentrations overall.[5] Nuciferine acts as an antagonist at serotonin 5-HT2A receptors, a partial agonist at dopamine D2 receptors, and an inhibitor of the DAT — a combined profile described as resembling atypical antipsychotics.[1]
The natural occurrence of apomorphine in N. caerulea is chemically contested. Early analyses attributed some of the plant's effects to apomorphine, a non-selective dopamine agonist used clinically for Parkinson's disease. Recent analytical work on authenticated extracts found apomorphine virtually absent.[5] Even if present, apomorphine's oral bioavailability is less than 2% due to extensive first-pass hepatic metabolism,[14] rendering oral preparations an ineffective delivery route for systemic apomorphine exposure.
Minor constituents include flavonoids, phytosterols, and uncharacterized alkaloids whose contribution to the psychoactive profile remains unknown. The closely related Nymphaea lotus demonstrates anxiolytic properties in rodent models,[13] suggesting the broader Nymphaea alkaloid milieu may contain bioactive compounds beyond nuciferine, though none have been individually characterized for N. caerulea.
Potency varies significantly across cultivars, harvest conditions, and commercial preparations. Dosoky and colleagues found that eleven commercial products did not resemble authenticated N. caerulea extracts in chemical composition,[5] underscoring both natural variability and the risk of species substitution in the commercial supply chain.
Oral bioavailability of nuciferine is approximately 3.8–4.2% in rats.[15] Nuciferine shows pH-dependent oral absorption, classified as well-soluble under acidic conditions but poorly absorbed under neutral or alkaline conditions.[16] No human pharmacokinetic data have been published, and the low oral bioavailability raises unresolved questions about what effective alkaloid concentrations reach the central nervous system via tea or tincture preparations.
Neuroscience[edit]
Where it acts
Nuciferine's combined 5-HT₂A antagonism, 5-HT₁A agonism, D2 partial agonism, and DAT inhibition collectively account for the sedative, anxiolytic, and mild perceptual effects reported with blue lotus.[1] The 5-HT1A agonism is associated with anxiolysis, while D2 partial agonism contributes to sedation. In rodent behavioural models, nuciferine blocked 5-HT2A agonist-induced head-twitch responses, substituted for clozapine in drug discrimination, and rescued PCP-induced prepulse inhibition disruption — without producing catalepsy.[1]
What it changes
The GABAergic system may also contribute: Nymphaea lotus extract potentiated pentobarbital-induced sleep in mice,[13] consistent with GABA-A involvement, though this has not been directly tested for nuciferine or N. caerulea preparations. Nuciferine distributes to brain, liver, and adipose tissue after administration, confirming central nervous system penetration.[15] CYP2D6 inhibition has been identified in vitro for related Nelumbo nucifera extracts,[17] raising the possibility of altered metabolism of co-administered drugs.
No neuroimaging studies with N. caerulea have been published. Key unresolved questions include: (1) what nuciferine plasma concentrations are achieved by human oral and inhaled preparations; (2) whether the low oral bioavailability (~4%) observed in rats translates to humans; and (3) whether constituents other than nuciferine contribute meaningfully to the psychoactive profile through unknown receptor interactions.[18]
Subjective Effects[edit]
Blue lotus produces a characteristically gentle sedative-oneirogenic experience. At lower doses, oral preparations yield mild relaxation, anxiolysis, and a sense of well-being; at higher doses or via inhaled routes, perceptual shifts and vivid hypnagogic imagery emerge. The oneirogenic quality — enhanced dream vividness and liminal-state imagery — is the defining experiential signature, most consistently reported in pre-sleep contexts. Set and setting modulate this dimension substantially, and preparation method determines both onset speed and intensity ceiling.
The experience occupies a pharmacological niche distinct from classical sedative-hypnotics. Nuciferine's receptor profile positions it closer to atypical antipsychotics than to benzodiazepines, yet at typical doses the subjective character more closely resembles a mild anxiolytic tea with dream-enhancing aftereffects than any clinical antipsychotic experience. The significant product adulteration risk means that the actual experience of any given commercial product may not reflect the pharmacology of authentic N. caerulea.
Effect Grid
Moderate sedation with noticeable anxiolysis and a mild euphoria. Thought deceleration is more pronounced, and focus suppression may be apparent. Oneirogenic effects — dreaming enhancement and sleep-transition hallucinations — are most consistently reported at this tier, particularly in pre-sleep contexts.
Physical effects include clear muscle relaxation, bodily heaviness, and physical fatigue. Nausea and dizziness are possible but generally mild. Motor control impairment may be noticeable.
Present-moment absorption and introspective qualities may emerge. Duration commitment is 2–4 hours for oral preparations. Driving and operating machinery should be avoided.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Sexual arousal enhancement · Dizziness · Nausea · Salivation · Stimulation · Yawning · Vomiting
Stimulation · Yawning · Vomiting
Information processing suppression · Humor enhancement · Confusion
Timeline · by preparation
Preparations[edit]
No published dose-response data exist for any N. caerulea preparation. All dose ranges below derive from community reports and are not clinically validated. Potency varies substantially between products and batches — start low and titrate cautiously.
Tea (oral)
Tea is the most traditional preparation. Dried flowers or petals are steeped in hot water for 10–20 minutes. Onset is gradual, typically 30–60 minutes, with total duration of 2–4 hours. The experience is characterized by mild sedation, gentle euphoria, and anxiolysis. Community-reported amounts range from 2–5 g of dried flower material per cup, though potency varies substantially between products. Tea preparation avoids combustion byproducts associated with smoking.
Smoked flower
Smoked flower involves smoking dried petals in a pipe or rolled preparation. Onset is rapid, typically within minutes, with total duration of 1–2 hours. Inhaled preparations produce more pronounced perceptual effects and altered mental status compared to oral routes.[3] Combustion introduces respiratory irritant risks not present with other preparations.
Vaporized resin or extract
Vaporized resin or concentrated extract, used in electronic cigarettes or vaporizers, produces the most rapid and intense effects.[9] Onset occurs within minutes, with perceptual disturbances and altered mental status more likely than with oral preparations.[3] Concentrated products carry the highest adulterant risk — synthetic cannabinoid lacing has been specifically documented in vaporized blue lotus products.[4] Dosing is particularly unreliable due to variable extraction concentrations and absent standardization.
Tincture (oral)
Tincture preparations involve alcohol extraction of dried flower material. Onset and duration are similar to tea (30–60 minutes onset, 2–4 hours total). Tinctures offer more consistent dosing than raw flower material but remain unstandardized. No regulatory body enforces alkaloid content labeling for blue lotus tinctures.
Infused wine
Infused wine — steeping flowers in wine — has historical precedent in ancient practice and remains a preparation method. Alcohol may alter absorption kinetics and adds its own sedative pharmacology. One clinical case in the published literature involved an infused beverage.[3]
Per-preparation dose tiers, timelines, and bioavailability data are in the Dose · by preparation card on this page.
Safety[edit]
- Acute toxicity
- Low
- Chronic toxicity
- Low
- Withdrawal
- None
- Tolerance buildup
- none
- Tolerance reset
- —
- Physical
- Negligible
- Psychological
- Negligible
- Compulsive redosing
- Negligible
- Dose escalation
- Negligible
- Cross-tol.
- —
Toxicity
No LD50 or formal acute toxicity data exist for N. caerulea or its preparations in any species.safety citation needed Clinical evidence is limited to a single case series: Schimpf and colleagues documented five military patients presenting with altered mental status after blue lotus use — four after vaping resin or extract and one after consuming an infused beverage.[3] All recovered with supportive care alone; no fatalities were documented.
Department of Defense adverse event data additionally document hallucinations, euphoria, paranoia, anxiety, slurred speech, decreased responsiveness, chest pain, rapid heartbeat, and seizure following blue lotus use.[4] Chest pain and tachycardia suggest cardiovascular involvement, though the mechanism is unclear and may reflect adulteration. No fatalities attributed to N. caerulea alone have been identified in published literature.
Contaminant and adulterant risk constitutes the most significant safety concern for blue lotus products.
Synthetic cannabinoid lacing: Blue lotus plant material has been commonly laced with synthetic cannabinoids — potent controlled substances that can produce seizure, cardiovascular collapse, and psychosis.[4]
Species misidentification: Eleven commercial products tested did not resemble authenticated N. caerulea extracts in chemical composition or aroma.[5] UC Berkeley research corroborates this finding, suggesting online products may consist of a different water lily species.[19]
No standardization: No regulatory body approves blue lotus for human consumption. No standardized alkaloid content requirements, GMP enforcement, or mandatory testing programs exist. Standard reagent test kits (Marquis, Mandelin) are not validated for blue lotus alkaloids. Fentanyl test strips do not detect synthetic cannabinoids. Laboratory LC-MS/MS or GC-MS analysis is required to confirm species identity and alkaloid content.
Blue lotus alkaloids (nuciferine, apomorphine) are not detectable on standard 5-, 10-, or 12-panel urine drug screens.[3] Products adulterated with synthetic cannabinoids may trigger positive results.
Psychological Risks
Dose-dependent perceptual disturbances, hallucinations, and confusion have been documented at high doses or via inhaled preparations.[3] Paranoia and anxiety are documented in military clinical reports.[4] Vaporized resin and extract produced more pronounced altered mental status than oral ingestion in the available case series.
No published data address precipitation of psychotic episodes in individuals with pre-existing vulnerability. Nuciferine's 5-HT₂A antagonism theoretically suggests low psychotomimetic risk relative to 5-HT2A agonists,[1] but this inference cannot be generalized to uncharacterized commercial preparations that may contain synthetic adulterants. Chronic psychological risks of repeated blue lotus use have not been studied.
Tolerance & Dependence
No published data on tolerance development, physical dependence, or withdrawal from N. caerulea or nuciferine in humans exist.safety citation needed Nuciferine's partial D2 agonism suggests theoretical dopaminergic tolerance may develop with repeated use, analogous to patterns seen with other D2 partial agonists, but this has not been investigated. No case reports of blue lotus dependence or withdrawal have been published. Absence of data does not indicate absence of risk.
Drug Interactions
CYP enzyme inhibition: Nelumbo nucifera leaf extract — which shares nuciferine with N. caerulea — contains potent in vitro CYP2D6 inhibitors, along with inhibitory activity on CYP2C9, CYP2C19, CYP2E1, and CYP3A4.[17] No human pharmacokinetic interaction studies exist, and clinical significance at typical blue lotus doses is unknown.
CYP2D6-metabolized drugs include codeine, tramadol, antidepressants (fluoxetine, paroxetine, venlafaxine), antipsychotics (haloperidol, risperidone), and beta-blockers (metoprolol). Co-administration with substantial blue lotus intake could theoretically elevate plasma concentrations of these medications, though this represents in vitro extrapolation from a related species, not a documented clinical interaction.
Pharmacodynamic interactions:
- Antipsychotics: Synergy or antagonism at D2 and 5-HT2A receptors. Nuciferine may augment or complicate antipsychotic dosing.
- Serotonergic antidepressants (SSRIs, SNRIs): DAT inhibition combined with serotonin receptor activity raises theoretical concern, though no clinical cases have been reported.
- MAO inhibitors (including Peganum harmala): Historical co-use documented archaeochemically.[2] MAOI co-administration could potentiate monoaminergic effects of blue lotus alkaloids.safety citation needed
- CNS depressants (alcohol, benzodiazepines, opioids): Additive sedation expected given nuciferine's sedative properties.
All interactions listed are mechanistically plausible but unsupported by clinical case reports or formal pharmacokinetic studies.
Contraindications
- Pregnancy and lactation: No published safety data exist. Use should be avoided.safety citation needed
- Psychiatric conditions: Given pharmacodynamic interactions with dopamine and serotonin receptor systems, use in individuals with psychotic disorders, bipolar disorder, or those taking psychotropic medications requires caution.
- Cardiovascular disease: Chest pain and tachycardia documented in adverse event reports.[4]
- Seizure disorders: At least one seizure documented in adverse event reports.[4] Whether this reflects intrinsic pharmacology or adulteration is unknown.
- Hepatic impairment: Given potential CYP enzyme inhibition and hepatic metabolism of nuciferine, altered drug metabolism may result.safety citation needed
- Military service: Blue lotus is prohibited for all U.S. service members including off-duty use per the DoD Prohibited Dietary Supplement Ingredients List.[4]
Harm Reduction[edit]
Forms & Identification
Blue lotus enters the market as dried flowers, pre-rolled blends, tinctures, concentrated resins, and vape cartridges. None of these carry verified alkaloid content labeling. Laboratory testing (LC-MS/MS or GC-MS) is the only reliable method to confirm species identity, alkaloid content, and absence of synthetic adulterants — standard reagent kits and fentanyl test strips cannot detect blue lotus alkaloids or synthetic cannabinoid contaminants.
Purchase from vendors who provide a Certificate of Analysis from an ISO-accredited laboratory. If a product produces effects inconsistent with mild sedation — particularly rapid-onset intense euphoria, strong dissociation, or acute anxiety — discontinue use immediately, as synthetic cannabinoid adulteration is a documented risk.
Guidelines
- Start with the lowest commonly reported dose for the preparation chosen. For tea, begin with 1–2 g of dried flower; for vaporized products, take a single small inhalation and wait 10 minutes before redosing.
- Use only one preparation method per session. Do not combine oral and inhaled routes.
- Do not use blue lotus products of unknown provenance. Products without third-party lab testing carry documented synthetic cannabinoid adulteration risk.
- If using for sleep or dream enhancement, consume 1–2 hours before intended sleep time and do not redose.
- Allow at least several days between uses until your individual response pattern is established.
Set & Setting
Blue lotus is best suited to calm, low-demand environments. The oneirogenic effects are most pronounced in pre-sleep settings. Avoid operating vehicles or machinery after use. If using an inhaled preparation for the first time, have a sober companion present — vaporized products produce more rapid and less predictable effects than oral preparations. Avoid combining with alcohol, which adds unpredictable sedation.
Aftercare & integration. Post-experience grogginess or residual sedation is common, particularly after higher doses or evening use. Hydrate and eat a light meal after the experience ends. If the experience produced anxiety or dysphoria, recognize that effects are self-limiting and typically resolve within 2–4 hours of onset.
Avoid redosing to counteract unwanted effects. If vivid dreams or disrupted sleep patterns persist beyond 24 hours after a single use, allow several days without use before reassessing.
Recovery & Support
No formal dependence or withdrawal has been documented for blue lotus, but habitual use of any psychoactive substance warrants self-assessment. If blue lotus use has become daily or near-daily, or if you find it difficult to sleep without it, consider tapering by reducing frequency before stopping entirely.
For general substance use concerns:
- SAMHSA National Helpline: 1-800-662-4357 (free, confidential, 24/7)
- SAMHSA online treatment locator: https://findtreatment.gov
- Crisis Text Line: Text HOME to 741741
If a blue lotus product was adulterated with synthetic cannabinoids and you experience ongoing symptoms after use, seek medical evaluation.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency:
- Severe confusion or unresponsiveness
- Chest pain or rapid heartbeat
- Seizure activity
- Intense paranoia, panic, or psychotic symptoms
- Breathing difficulty
Immediate steps:
- 1. Do not leave the person alone.
- 2. If the person is unconscious or seizing, place them in the recovery position.
- 3. Call emergency services (911 in the US, 112 in the EU, 999 in the UK) if symptoms include seizure, chest pain, loss of consciousness, or breathing difficulty.
- 4. Do not attempt to induce vomiting.
- 5. Remove any vaporizer or smoking material from the area.
What to tell the dispatcher:
- That the person consumed a blue lotus product (specify preparation: vape, tea, resin, etc.)
- Approximate amount and time of consumption
- Current symptoms
- Whether any other substances were consumed
- Good Samaritan laws exist in many jurisdictions — calling for help should not result in legal consequences for drug use.
Reversal agents: No specific reversal agent exists for blue lotus. If synthetic cannabinoid adulteration is suspected, treatment is supportive. Benzodiazepines may be administered by medical professionals for seizures.
Legal Status[edit]
Nymphaea caerulea is not scheduled under the 1961 Single Convention on Narcotic Drugs, the 1971 Convention on Psychotropic Substances, or the 1988 UN Convention Against Illicit Traffic. Neither nuciferine nor apomorphine is internationally scheduled.[20] Most jurisdictions permit sale and possession, while a small number have enacted specific bans. The principal legal risk for consumers in unregulated markets is the presence of synthetic cannabinoid adulterants, which are controlled substances in most jurisdictions and can result in criminal liability regardless of the plant's own legal status.
| Jurisdiction | Status | Notes |
|---|---|---|
| United States (federal) | Unscheduled | Not a controlled substance under the Controlled Substances Act. Not FDA-approved for human consumption; cannot be legally marketed as a dietary supplement or food ingredient[20] |
| Louisiana (US) | Banned for human consumption | Prohibited since 2005 under Act No. 159, which banned 40 plants including N. caerulea when intended for human consumption. Exempt for aesthetic, landscaping, or decorative purposes[20] |
| US Military | Prohibited | Banned for all service members including off-duty use per the DoD Prohibited Dietary Supplement Ingredients List[4] |
| Russia | Banned | Scheduled since April 2009 under Federal Law on Narcotic Drugs, alongside Salvia divinorum and Argyreia nervosa[21] |
| Poland | Banned | Scheduled since March 2009[21] |
| Latvia | Banned | Controlled substance[21] |
| United Kingdom | Uncertain | Not specifically named in the Misuse of Drugs Act 1971. May fall under the Psychoactive Substances Act 2016 if sold for human consumption; personal possession generally considered legalcitation needed |
| Canada | Legal | Not classified as a controlled substance. Legal for sale and possession; therapeutic claims require licensingcitation needed |
| Germany | Legal | Permitted under general herbal product regulationscitation needed |
| Netherlands | Legal | Available in smart shops; not scheduledcitation needed |
| Australia | Legal (uncontrolled) | Not a controlled substance. Not TGA-approved for human consumption or therapeutic use. Typically marketed for aromatic or ceremonial purposes[20] |
Apomorphine circulates as a regulated prescription pharmaceutical in jurisdictions where it is approved for Parkinson's disease and erectile dysfunction, but this regulatory status pertains to the manufactured drug product, not to plant material containing trace quantities. The plant's alkaloids are not controlled under any international drug treaty.
references
- [1]
- [2] ^abcTanasi D, van Oppen de Ruiter BF, Florian F, et al. (2024) Multianalytical investigation reveals psychotropic substances in a Ptolemaic Egyptian vase — Scientific Reports doi:10.1038/s41598-024-78721-8
- [3]
- [4]
- [5]
- [6] ^abcBertol E, Fineschi V, Karch SB, Mari F, Riezzo I (2004) Nymphaea cults in ancient Egypt and the New World: a lesson in empirical pharmacology — Journal of the Royal Society of Medicine PMID:14749409